Cancer continues to be a big area of investor interest and Surface Oncology now aims to tap into that with an initial public stock offering that the company hopes will finance tests of its lead immuno-oncology drug.
Surface set a preliminary $75 million goal for the stock offering, according to documents filed with securities regulators late Friday. Surface has applied for a listing on the Nasdaq exchange under the stock symbol “SURF.”
Surface has been developing drugs that could be paired with so-called checkpoint inhibitors, a type of immunotherapy that removes the brakes on the body’s cancer-killing T cells. Surface’s… Read more »
UNDERWRITERS AND PARTNERS